Est-il important de s’améliorer rapidement dans le RP ?
OP0028. Snoeck Henkemans S, De Jong P, Luime J et al. Early achievement of minimal disease activity in psoriatic arthritis is associated with long-term improvements in quality of life. Eular…
Site professionnel spécialisé en Rhumatologie
OP0028. Snoeck Henkemans S, De Jong P, Luime J et al. Early achievement of minimal disease activity in psoriatic arthritis is associated with long-term improvements in quality of life. Eular…
P0058. Østergaard M, Van Vollenhoven R, Rudin A et al. Certolizumab-pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: clinical and radiographic 48-weeks results of the investigator-initiated randomized…
OP0066. Caillet-Portillo D, Puéchal X, Degboe Y et al. Impact of diagnosis and treatment of tropheryma whipplei infection in patients with pre-existing chronic inflammatory rheumatic diseases: data from the national…
OP0059. Antovic A, Vedder D, Rudin A et al. Profound anticoagulant effects of initial antirheumatic treatments in early rheumatoid arthritis patients: a NORD-STAR spin-off study. Eular 2022.
OP0018. Proft F, Muche B, Rios Rodriguez V et al. Comparison of the effect of treatment with NSAIDS added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural…
OP0257. Cordtz R, Askling J, Delcoigne B et al. Risk of haematological malignancy in patients with psoriatic arthritis, overall and in relation to TNF inhibitors - a Nordic cohort study.…
OP0183. Fernández-Fernández E, Monjo I, Peiteado D et al. Validity of the Eular recommendations on the use of ultrasound in the diagnosis of giant cell arteritis. Eular 2022. OP0184. de…
OP0017. Landevé RBM, Poddubnyy D, Rahman P et al. Recapture rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomized placebo-controlled…
OP0182. Wenhoff N, Schmidt WA, Bergner R et al. Secukinumab in giant cell arteritis: the randomised, parallel-group, double-blind, placebo-controlled, multicentre phase 2 TitAIN trial. <strong>Figure 1 - Diagramme Kaplan-Meier du…
POS0073. Lindström U, Di Giuseppe D, Exarchou S et al. Comparison of time from methotrexate initiation to start of a b/tsDMARD in psoriatic arthritis versus rheumatoid arthritis. A nationwide register-based…
OP0135. Meissner Y, Albrecht K, Kekow J et al. Risk of cardiovascular events under janus kinase inhibitors in patients with rheumatoid arthritis: observational data from the German RABBIT register. Eular…
OP0138. Sánchez-Alonso F, Bohórquez C, Diaz-Torne C et al. Risk of cancer after biologic and targeted synthetic DMARDs initiation in patients with rheumatic diseases and a history of prior malignancy:…
OP0016. Deodhar A, Van den Bosch F, Poddubnyy D et al. Efficacy and safety of upadacitinib in patients with active non-radiographic axial spondyloarthritis: a double-blind, randomized, placebo-controlled phase 3 trial.…
OP0255. Merola JF, McInnes I, Ritchlin CT et al. Bimekizumab in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: 16-week efficacy & safety from…
OP0221. Ruperto N, Chertok E, Dehoorne J et al. Efficacy of secukinumab in enthesitis-related arthritis: results from a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 study (JUNIPERA). Eular 2022. Figure…
